- Home
- PSNL vs MREO Comparison
PSNL vs MREO Comparison
Compare PSNL & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- MREO
- Stock Information
- Founded
- PSNL 2011
- MREO 2015
- Country
- PSNL United States
- MREO United Kingdom
- Employees
- PSNL N/A
- MREO N/A
- Industry
- PSNL Medical Specialities
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- PSNL Health Care
- MREO Health Care
- Exchange
- PSNL Nasdaq
- MREO Nasdaq
- Market Cap
- PSNL 460.7M
- MREO 424.5M
- IPO Year
- PSNL 2019
- MREO N/A
- Fundamental
- Price
- PSNL $4.63
- MREO $2.15
- Analyst Decision
- PSNL Strong Buy
- MREO Strong Buy
- Analyst Count
- PSNL 5
- MREO 7
- Target Price
- PSNL $8.00
- MREO $7.71
- AVG Volume (30 Days)
- PSNL 742.2K
- MREO 943.2K
- Earning Date
- PSNL 05-06-2025
- MREO 05-13-2025
- Dividend Yield
- PSNL N/A
- MREO N/A
- EPS Growth
- PSNL N/A
- MREO N/A
- EPS
- PSNL N/A
- MREO N/A
- Revenue
- PSNL $85,694,000.00
- MREO N/A
- Revenue This Year
- PSNL $1.16
- MREO N/A
- Revenue Next Year
- PSNL $25.58
- MREO $54.91
- P/E Ratio
- PSNL N/A
- MREO N/A
- Revenue Growth
- PSNL 15.57
- MREO N/A
- 52 Week Low
- PSNL $1.14
- MREO $1.58
- 52 Week High
- PSNL $7.20
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- PSNL 53.76
- MREO 40.94
- Support Level
- PSNL $4.44
- MREO $2.12
- Resistance Level
- PSNL $5.06
- MREO $2.27
- Average True Range (ATR)
- PSNL 0.30
- MREO 0.13
- MACD
- PSNL -0.07
- MREO -0.02
- Stochastic Oscillator
- PSNL 19.83
- MREO 9.09
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).